IL17A and psoriasis: An international, prospective, non-interventional, study(PSoHO) compared the effectiveness of anti-interleukin (IL)-17A biologics (ixekizumab and secukinumab) to other approved biologics and the pairwise comparative effectiveness of ixekizumab relative to five other individual biologics for patients with moderate-to-severe psoriasis.